CHALFONT ST GILES, England, & SOLNA, Sweden--(BUSINESS WIRE)--GE Healthcare (NYSE:GE) signed an agreement with Affibody AB (“Affibody”) to collaborate on the development of a Her2-targeted PET imaging agent, which is scheduled to begin clinical trials later this year.
